LIMNW Liminatus Pharma, Inc. - Warrants

0.0437USD+37.07%Mkt Cap: —P/E: —8d ago

Liminatus Pharma, Inc., a pre-clinical stage biopharmaceutical company, engages in the development of cancer therapies in the United States. It develops IBA101, a humanized anti CD47 monoclonal antibody, which is in Phas…

Key Statistics

Company

Market Cap—

Enterprise Value—

Revenue (TTM)—

Gross Profit—

Net Income (TTM)-10.21M USD

Revenue/Share—

Last Price0.0437 USD

Fiscal Year End—

MR Quarter—

Employees1

CountryUS

Sector—

Industry—

ISIN—

Valuation

P/E (Trailing)—

P/E (Forward)—

PEG—

EV/EBITDA—

EV/Revenue—

P/S—

P/B0.18

EPS (TTM)—

EPS (Forward)—

52W Range

0.037014% of range0.0833

52W High0.0833 USD

52W Low0.0370 USD

Profitability

Gross Margin0.00%

Oper. Margin0.00%

EBITDA Margin0.00%

Profit Margin0.00%

ROE103.99%

ROA-1990.37%

Growth

Revenue Growth—

Earnings Growth—

Cash Flow & Leverage

Operating CF-9.96M USD

CapEx (TTM)13.11K USD

FCF Margin—

FCF Yield—

Net Debt-1.57M USD

Net Debt/EBITDA0.39

Balance Sheet

Debt/Equity-0.15

Current Ratio1.12

Quick Ratio0.99

Book Value/Sh0.27 USD

Cash/Share2.25 USD

Dividends

Fwd Div Rate—

Trail. Div Rate0.00 USD

Div. Yield—

5Y Avg Yield—

Payout Ratio—

Ex-Div Date—

Pay Date—

Analyst Consensus

Rating—

Target (Mean)—

Target Range—

# Analysts—

Ownership

Shares Out.—

Float919.25K

Insiders—

Institutions—

Technical

SMA 50—

SMA 200—

Beta0.75

S&P 52W Chg15.78%

Avg Vol (30d)1.81K

Avg Vol (10d)—

Technical Indicators

RSI (14)47.8

MACD-0.0025

MACD Signal-0.0028

MACD Hist.+0.0003

BB Upper0.0689 USD

BB Middle0.0528 USD

BB Lower0.0367 USD

BB Width60.95%

ATR (14)0.0107 USD

Vol Ratio (20d)0.45x